related documents
- A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma Conferences
- The impact of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of anticancer agents, as perceived by patients, physicians and institution review board members (IRBs) Conferences
- Use of venous access devices in patients younger than 21 years of age Conferences